India’s BFSI sector is undergoing its most consequential technology transition in a generation. The industry’s market cap is at ₹91 trillion ($1.1 trillion+), with India’s fintech adoption rate standing at 87%, far above the global average of 67%. Digital payments alone may cross $10 trillion by 2026, driven by UPI, Aadhaar, and mobile penetration. Yet beneath these headline numbers, a structural gap persists. Indian BFSI entities currently allocate just 3 to 5% of revenue to technology, against global peers spending 8 to 10%. The platforms processing India’s banking transactions are frequently running on architecture built for a different era.
Pharma faces a parallel reckoning. India’s pharmaceutical sector, valued at nearly $65 billion, supplies approximately 20% of the world’s generic medicines — and aspires to build a $130 billion market by 2030. The global pharma digital transformation market, valued at $18.4 billion in 2023, is expected to reach $45.2 billion by 2030, with 63% of pharma CEOs now citing digital transformation as a top priority for revenue growth. But HCP engagement platforms, pharmacovigilance workflows, and supply chain systems in most Indian pharma companies remain fragmented, legacy-dependent, and unready for the AI era.
These two sectors, high stakes, high complexity, and chronically under-digitised, are precisely where INT. has built its deepest delivery expertise.
What 28 Years of Enterprise Delivery Actually Looks Like
Founded in Kolkata in 1997 by Abhishek Rungta with a ₹50 investment and a conviction that Indian technology talent could serve global enterprises, INT. has grown into a 1,100+ professional enterprise operating across 45 countries from six global offices. It has delivered for IndusInd Bank, SBI General Insurance, DCB Bank, Bajaj Allianz Life Insurance, and Ageas Insurance (UK) in BFSI, and for Cipla in Life Sciences, among a 500+ client portfolio spanning Tesco, Honeywell, and Somax Inc. (USA).
The outcomes are not theoretical. A multilingual offline-ready portal built for SBI General Insurance delivered a 62% reduction in support requests and a 3x increase in claim tracker adoption among policyholders in Tier-2 and Tier-3 markets. A website redesign for DCB Bank produced a 70% improvement in mobile usability and a 40% reduction in bounce rate. For Bajaj Allianz Life Insurance, INT. automated the sales performance MIS process, eliminating manual reporting that had consumed dozens of hours of leadership time each week. For Ageas Insurance (UK), INT. built a mature product from scratch, now deployed at hundreds of sites across Europe.
These are not case studies. They are operating metrics inside India’s most scrutinised financial institutions.
The Full-Stack Difference
What distinguishes INT. from the niche vendors that crowd India’s enterprise technology market is the breadth of capability delivered under a single partnership. Leading pharma companies are now embedding AI, automation, and digital twins into every layer of the enterprise, connecting R&D, manufacturing, commercial, and supply chain into a single responsive network. INT.’s Life Sciences practice, anchored by its Cipla engagement, is precisely positioned to deliver that integration without the client managing multiple vendor relationships.
Recognised five consecutive times as a Great Place to Work, ranked in the Deloitte Technology Fast 50 and Fast 500 Asia Pacific, and now a pre-IPO company with DRHP filed in 2024, INT. is entering a new chapter, with the same foundational conviction Abhishek Rungta had in 1997: that technology is only worth building if it makes a measurable difference to the business it serves.
For India’s banks, insurers, and pharma companies, that difference has been quietly compounding for nearly three decades.
INT. (Indus Net Technologies) is a full-stack digital transformation company headquartered in Kolkata, India. With 1,100+ professionals, 500+ enterprise clients across 45 countries. INT. delivers AI, Cloud, Cybersecurity, Digital Engineering, and Customer Experience solutions for BFSI, Life Sciences, and Retail enterprises. Learn more at intglobal.com.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
